Nearly one-third of insured adults with diagnosed hypertension were nonadherent to their antihypertensive medications in 2015, according to a report published Nov. 4 in Hypertension.

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted unanimously Nov. 14 to recommend an expanded indication for icosapent ethyl, a purified omega-3 product designed to help heart patients keep their lipid levels in check.

Living with chronic stress could have serious implications for blood pressure control in black patients, Reuters reported Nov. 5.

A study out of the University of Pennsylvania School of Nursing suggests that weight loss achieved through a combination of intensive behavioral therapy and 3 milligrams of liraglutide daily results in optimal weight-related quality of life for patients struggling with obesity.

A novel risk calculator developed by researchers at the Cleveland Clinic encourages patients with both type 2 diabetes and obesity to weigh their treatment options for optimal long-term health.

A study published in Hypertension this month has found that exercise—historically one of our best first-line defenses against cardiovascular disease—could also negatively impact heart health in certain situations, including at work.

Finalized results from the OSLER-1 trial—the longest-running study of PCSK9 inhibitors to date—suggest evolocumab is safe and “consistently excellent” at lowering LDL-cholesterol through five years.

The largest study of its kind has found that taking blood pressure medication at bedtime—as opposed to first thing in the morning—lowers heart patients’ risk of death and CV-related illness in the long run.